Advertisement

Current Psychiatry Reports

, 17:529 | Cite as

Psychopharmacology in Cancer

  • Seema M. ThekdiEmail author
  • Antolin Trinidad
  • Andrew Roth
Complex Medical-Psychiatric Issues (MB Riba, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Complex Medical-Psychiatric Issues

Abstract

Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient’s quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.

Keywords

Cancer Psychopharmacology Depression Anxiety Cancer-related symptoms Psycho-oncology 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Seema M. Thekdi, Antolin Trinidad, and Andrew Roth declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Mitchell AJ et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology (Williston Park). 1999;13(9):p. 1293–301. Discussion 1301–2, 1305–6.Google Scholar
  3. 3.
    Holland JC et al. Distress management. J Natl Compr Canc Netw. 2013;11(2):190–209.PubMedGoogle Scholar
  4. 4.
    American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders DSM-5, 5th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  5. 5.
    Lee BN et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11(5):279–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Thekdi SM IM, Dunn L. Psychopharmacological interventions. In: Grassi RM, editor. Clinical psych-oncology: an international perspective. Chichester: Wiley-Blackwell; 2012. p. 109–26.CrossRefGoogle Scholar
  7. 7.
    Desplenter F et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br J Cancer. 2012;107(9):1644–51.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ng CG et al. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22(4):762–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Caruso R et al. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393.PubMedCrossRefGoogle Scholar
  10. 10.•
    Grassi L et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014;26(1):44–62. This review article includes a search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) and summarizes relevant data concerning the efficacy and safety of pharmacotherapy for cancer-related psychiatric disorders in cancer patients across the trajectory of the disease.PubMedCrossRefGoogle Scholar
  11. 11.
    McDaniel JS et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52:89–99.PubMedCrossRefGoogle Scholar
  12. 12.
    Sharpe M et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer. 2004;90(2):314–20.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Strouse TB. Psychopharmacologic treatment of depression in patients with cancer: a 2013 update. FOCUS 2013. 2013;11:450–9.Google Scholar
  14. 14.
    Stockler MR, O’Connell R, Nowak AK, et al. Effects of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007;8:603–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Miller AH. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2008;65(9):p. 732–741.CrossRefGoogle Scholar
  16. 16.
    Danzer R, O’Connor J, Freund GG. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.CrossRefGoogle Scholar
  17. 17.
    Tynan RJ et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26(3):469–79.PubMedCrossRefGoogle Scholar
  18. 18.
    Mun AR et al. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33(9):3691–7.PubMedGoogle Scholar
  19. 19.
    De Fazio P et al. Mental adjustment to cancer: the role of anxious and depressive symptoms under treatment. Int J Psychiatry Med. 2013;46(4):375–86.PubMedCrossRefGoogle Scholar
  20. 20.
    Strong V et al. Management of depression for people with cancer 4 (SMaRT oncology 1): a randomised trial. Lancet. 2008;372(9632):40–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Holland JC et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7(4):291–300.PubMedCrossRefGoogle Scholar
  22. 22.
    Fisch MJ et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21(10):1937–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Schillani G et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases. Tumori. 2011;97(3):358–61.PubMedGoogle Scholar
  24. 24.•
    Lydiatt WM et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol-Head Neck Surg. 2013;139(7):p. 678–686. This is an interesting study suggesting that certain depressive states can be prevented, in turn abutting the issue of whether certain depressive states in cancer may be explained by biochemically identifiable mechanisms such as inflammation.Google Scholar
  25. 25.•
    Callari A et al. Treatment of depression in patients with breast cancer: a critical review. Tumori. 2013;99(5):p. 623–633. This article reviews the relevant evidence for the efficacy of SSRIs in breast cancer. The importance of the study is that it separates certain forms of pharmacologically treatable depression from general distress in cancer patients.Google Scholar
  26. 26.
    Kim SW et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Moss EL et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15(3):259–67.PubMedCrossRefGoogle Scholar
  28. 28.
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.PubMedGoogle Scholar
  29. 29.
    Smith EM et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Amr YM, Yousef AA. Evaluation of efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J Pain. 2010;26(5):381–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Durand JP et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.PubMedCrossRefGoogle Scholar
  32. 32.
    L’Esperance S et al. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21(5):1461–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5–6):333–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Kelly CM et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J. 2010;340.Google Scholar
  36. 36.
    Regan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441–51.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Rae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452–60.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Zembutsu H et al. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011;11(2):185–93.PubMedCrossRefGoogle Scholar
  39. 39.
    Ahmad A, Shahabuddin S, Sheikh S. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther. 2010;88(6):814–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Portenoy RK et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326–36.PubMedCrossRefGoogle Scholar
  41. 41.
    Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manag. 1998;16(3):193–8.CrossRefGoogle Scholar
  42. 42.
    Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37(1):57–62.PubMedCrossRefGoogle Scholar
  43. 43.
    Bruera E et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992;50(1):75–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30(2):100–7.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care. 2012;29(6):483–90.PubMedCrossRefGoogle Scholar
  46. 46.
    Minton O et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7, CD006704.PubMedGoogle Scholar
  47. 47.
    Roth AJ et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116(21):5102–10.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Bruera E et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31(19):2421–7.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Moraska AR et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–9.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Jean-Pierre P et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Spathis A et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32(18):1882–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–14.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Yoon HJ et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;13:240.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Boettger S, Breitbart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care. 2011;9(4):351–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008;24(4):657–722. vii.PubMedCrossRefGoogle Scholar
  56. 56.•
    Wang HR, Woo YS, Bahk WM. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci. 2013;67(5):p. 323–31. This paper reviews six prospective, randomized controlled studies evaluating the efficacy, safety, and tolerability of atypical antipsychotics in the treatment of delirium.CrossRefGoogle Scholar
  57. 57.
    Yoon HK et al. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica. 2011;23(4):179–83.PubMedCrossRefGoogle Scholar
  58. 58.
    Anderson R et al. Lurasidone for the management of intensive care unit (ICU)-associated delirium. Crit Care Med. 2012;40(12):1–328.Google Scholar
  59. 59.•
    Teslyar P et al. Prophylaxis with antipsychotic medication reduces the risk of post-operative delirium in elderly patients: a meta-analysis. Psychosomatics. 2013;54(2):p. 124–31. This paper reviews five studies examining the use of antipsychotics (haloperidol, risperidone, and olanzapine) in the prevention of postoperative delirium in elderly patients. Pooled analysis revealed a relative risk reduction of 50 % versus placebo.CrossRefGoogle Scholar
  60. 60.
    Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159–61.PubMedCrossRefGoogle Scholar
  61. 61.
    Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care. 2013;30(1):75–82.PubMedCrossRefGoogle Scholar
  62. 62.
    Han C et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851–70.PubMedCrossRefGoogle Scholar
  63. 63.
    Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30(9):942–51.PubMedCrossRefGoogle Scholar
  64. 64.
    McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27(2):132–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Smith HH. Palliative Medicine. Philadelphia: Saunders Elsevier; 2009. p. 894–8.CrossRefGoogle Scholar
  66. 66.
    Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22(4):1143–51.PubMedCrossRefGoogle Scholar
  67. 67.
    Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8):951–6.PubMedCrossRefGoogle Scholar
  68. 68.•
    Rahman T et al. Antipsychotic treatment in breast cancer patients. Am J Psychiatry. 2014;171(6):p. 616–21. This paper reviews the issue of prescribing antipsychotics in the context of breast cancer, a concern often raised by patients to their clinicians requiring the most up-to-date information.CrossRefGoogle Scholar
  69. 69.
    Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.PubMedCrossRefGoogle Scholar
  70. 70.
    Linden W et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2–3):343–51.PubMedCrossRefGoogle Scholar
  71. 71.
    Noyes R, Holt C, Massie M. Anxiety disorders. In: Holland J, editor. Psycho-oncology. New York: Oxford University Press; 1998. p. 548–63.Google Scholar
  72. 72.
    Miller K, Massie MJ. Depression and anxiety. Cancer J. 2006;12(5):388–97.PubMedCrossRefGoogle Scholar
  73. 73.
    Prieto JM et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20(7):1907–17.PubMedCrossRefGoogle Scholar
  74. 74.
    Lavigne JE et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136(2):479–86.PubMedCrossRefGoogle Scholar
  75. 75.•
    Lindgren ME et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013;22(8):p. 1889–94. The results of this study suggest that beta-blocker use may benefit cancer patients’ psychological adjustment following diagnosis, and provide a promising direction for future investigations on the pharmacological benefits of beta-blockers for cancer-related distress.CrossRefGoogle Scholar
  76. 76.
    Dundar Y et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004;19(5):305–22.PubMedCrossRefGoogle Scholar
  77. 77.
    Terzano MG et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261–82.PubMedCrossRefGoogle Scholar
  78. 78.
    Moore TA, Berger AM, Dizona P. Sleep aid use during and following breast cancer adjuvant chemotherapy. Psychooncology. 2011;20(3):321–5.PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14(5):563–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Joffe H et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17(5):908–16.PubMedCrossRefGoogle Scholar
  81. 81.
    Candy B et al. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database Syst Rev. 2012;10:Cd004596.PubMedGoogle Scholar
  82. 82.
    Testa A et al. Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:65–85.PubMedGoogle Scholar
  83. 83.•
    Vaidya R et al. Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. Oncology. 2011;81(1):p. 9–11. This study reports the percentage of breast cancer survivors (almost 8 %) receiving ongoing benzodiazepines and the circumstances surrounding their usage following 1000 consecutive women with breast cancers.CrossRefGoogle Scholar
  84. 84.
    Altamura AC et al. Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Rev Neurother. 2011;11(1):85–99.PubMedCrossRefGoogle Scholar
  85. 85.
    Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer Chemother Pharmacol. 2011;67(3):489–501.PubMedCrossRefGoogle Scholar
  86. 86.
    Eisenberg E et al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67(9):1265–89.PubMedCrossRefGoogle Scholar
  87. 87.
    Petrini M, Azzara A. Lithium in the treatment of neutropenia. Curr Opin Hematol. 2012;19(1):52–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Khasraw M et al. Using lithium as a neuroprotective agent in patients with cancer. BMC Med. 2012;10:131.PubMedCentralPubMedCrossRefGoogle Scholar
  89. 89.
    Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007;7(1):9–16.PubMedCrossRefGoogle Scholar
  90. 90.
    Andersohn F et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010;75(4):335–40.PubMedCrossRefGoogle Scholar
  91. 91.
    Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013;118(4):859–65.PubMedCrossRefGoogle Scholar
  92. 92.
    Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30(8):1385–407.PubMedCrossRefGoogle Scholar
  93. 93.
    Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. J Clin Oncol. 2011;29(29):3842–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Loprinzi CL et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28(4):641–7.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Bar Ad V. Gabapentin for the treatment of cancer-related pain syndromes. Rev Recent Clin Trials. 2010;5(3):174–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Bennett MI et al. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;14(11):1681–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Anand S. Gabapentin for pruritus in palliative care. Am J Hosp Palliat Care. 2013;30(2):192–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3):424–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;12, CD006044.PubMedGoogle Scholar
  101. 101.
    Bendaly EA et al. Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther. 2007;4(4):241–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Reas DL, Grilo CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014;19:99–142.PubMedCrossRefGoogle Scholar
  103. 103.
    Argyriou AA et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Seema M. Thekdi
    • 1
    Email author
  • Antolin Trinidad
    • 2
  • Andrew Roth
    • 3
  1. 1.The University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of PsychiatryNorwalk HospitalNorwalkUSA
  3. 3.Memorial Sloan-Kettering Cancer CenterWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations